Guggenheim started coverage on shares of Covetrus (NASDAQ:CVET) in a report published on Thursday, BenzingaRatingsTable reports. The brokerage issued a neutral rating on the stock.
Other equities analysts have also recently issued reports about the stock. Svb Leerink reaffirmed an outperform rating on shares of Covetrus in a research note on Wednesday, March 20th. Zacks Investment Research cut shares of Covetrus from a hold rating to a sell rating in a research note on Friday, April 19th. Stifel Nicolaus assumed coverage on shares of Covetrus in a research note on Wednesday, May 22nd. They set a hold rating and a $30.00 price target for the company. Raymond James assumed coverage on shares of Covetrus in a research note on Wednesday, February 27th. They set an outperform rating and a $45.00 price target for the company. Finally, Cleveland Research assumed coverage on shares of Covetrus in a research note on Friday, May 10th. They set a hold rating for the company. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company’s stock. Covetrus currently has a consensus rating of Hold and a consensus price target of $36.67.
CVET stock opened at $26.13 on Thursday. Covetrus has a 12 month low of $24.83 and a 12 month high of $43.83. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.82 and a quick ratio of 0.93.
Covetrus (NASDAQ:CVET) last released its quarterly earnings results on Wednesday, May 15th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.03). The company had revenue of $941.00 million for the quarter, compared to analysts’ expectations of $993.41 million. During the same period in the previous year, the company posted $0.18 earnings per share. The company’s revenue for the quarter was down .6% compared to the same quarter last year. On average, sell-side analysts expect that Covetrus will post 0.63 EPS for the current fiscal year.
In related news, Director Betsy S. Atkins sold 150,845 shares of Covetrus stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $27.80, for a total transaction of $4,193,491.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Timothy Ludlow sold 81,498 shares of Covetrus stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $28.01, for a total transaction of $2,282,758.98. The disclosure for this sale can be found here. Insiders have sold a total of 233,028 shares of company stock valued at $6,495,656 in the last quarter.
Covetrus Company Profile
Covetrus, Inc engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.
Recommended Story: The basics of gap trading strategies
Receive News & Ratings for Covetrus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covetrus and related companies with MarketBeat.com's FREE daily email newsletter.